Outcome
| Five years of follow-up achieved (n, %) | 28 (93.3) |
| Average follow-up period (months) | 58±21 |
| MACE (n, %) | 1 (3.3) |
| NFE (n, %) | 11 (36.6) |
| De novo PCI (n, %) | 7 (23.3) |
| TLR (n, %) | 7 (23.3) |
| BMS (n, %) | 3 (42.9) |
| DES (n, %) | 4 (57.1) |
| Cerebral infarction (n, %) | 2 (6.7) |
| Non-cardiac-related death (n, %) | 5 (16.7) |
BMS, bare-metal stents; DES, drug-eluting stents; MACE, major adverse cardiovascular events; NFE, non-fatal coronary events; PCI, percutaneous coronary intervention; TLR, target lesion revascularisation.